WHO ICTRP trial
A multicenter, open label, phase I / II study to evaluate safety…
NL-OMON39531 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON39531 |
|---|---|
| Public title | A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. |
| Scientific title | A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. - BIBF 1120 in HCC |
| Primary sponsor | Boehringer Ingelheim |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Austria;Germany;Hungary;Netherlands ;Poland;Romania;Slovakia;Switzerland;United Kingdom |
| Conditions | hepatocellular carcinoma liver cancer;10019815;hepatocellular carcinoma;liver cancer |
| Interventions | Patents are treated with Sorafenib or BIBF1120. ;BIBF 1120;hepatocellular carcinoma;Sorafenib |
| Registration date | Sep 19, 2014 |
| Target size | 1 |
| Secondary IDs | 2009-011925-14;NL38928.041.12 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: